Navigation Links
Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
Date:2/23/2012

PALO ALTO, Calif., Feb. 23, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $2.5 million, or $0.05 per share, for the three months ended December 31, 2011, compared with a net loss of $9.8 million, or $0.18 per share, for the comparable period in 2010.  For the year ended December 31, 2011, net loss was $12.0 million, or $0.22 per share, compared with a net loss of $24.7 million, or $0.46 per share, for the year ended December 31, 2010.

For the quarter ended December 31, 2011, total operating costs and expenses were $2.5 million compared with $11.0 million in the fourth quarter of 2010, representing a reduction of approximately 77%. Operating costs and expenses in the 2010 fourth quarter included facility exit costs of $5.4 million associated with the relocation of our corporate offices and a restructuring charge of $0.4 million comprised of employee severance and related costs, for which there were none in 2011. Excluding facility exit costs and the restructuring charge, total operating costs and expenses were approximately 52% lower in the fourth quarter of 2011 compared with the same period in 2010 primarily due to lower facilities, headcount and clinical development expenses.  Also included in the fourth quarter of 2010 was $1.2 million in grants for Qualifying Therapeutic Discovery Projects awarded by the U.S. Government which was reported as other income. No such grant was awarded in 2011.

Operating costs and expenses for the year ended December 31, 2011 were $12.1 million, compared with $26.1 million for the same period in 2010. Operating costs and expenses in 2011 included approximately $1.6 million in stock-based compensation expense compared to $2.1 million in 2010. Excluding the facility exit costs and restructuring charge in the fourth quarter of 2010, the reduction in operating costs and expenses of approximately 40% in the
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
2. Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
3. Telik Announces Third Quarter 2011 Financial Results
4. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
5. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
7. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
8. Telik Announces First Quarter 2011 Financial Results
9. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
10. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
11. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 /PRNewswire/ ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... shares of its common stock and Series C ... stock.  Funds under the management of QVT Financial ...
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... March 1, 2012 Today, the Pharmacy Technician ... Survey to collect feedback from the pharmacy profession ... Recommendations include the creation of specialty pharmacy technician ... as requiring a minimum period of practical experience, ...
... Corporation (NYSE: BSX ) announces the ... Coronary Stent System in Japan.  The product was ... and Welfare.  The PROMUS Element Stent System incorporates ... stent design and an advanced catheter delivery system ...
Cached Medicine Technology:PTCB Calls For Profession-wide Feedback on Proposed Changes to Certification Program 2Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan 2Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan 3Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan 4
(Date:12/24/2014)... National (PRWEB) December 25, 2014 Over ... back to their local communities. That is 700 smiling ... a single gift. Additionally over $6000 in monetary donations ... help offset some of the expenses they incur through ... years drive were A Child's Haven , Shrine's ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... dietary detoxification. The second study is scheduled to begin ... test patients who just completed a 21-day detoxification regimen. ... conducting the study, Dr. Casad said, "About 10 years ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... mount in a mass tort litigation currently underway in ... reports. As of December 24, 2014, court documents ... proceeding on behalf of individuals who developed gynecomastia (male ... use. Data from the Court indicates that this represents ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... UWDress.com, the famous women’s dress supplier, has presented its new ... wedding gown promotion. , For those who prefer ... way, the collection should be a great choice. The dresses ... they are available with custom service. , Now, all the ... to 75% off; most of them come in hot designs. ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... for the Bush administration and therefore many issues are closing ... by the American Civil Liberties Union; they have asked for ... ‘Abstinence Only Sex Education’ programme. ,The ACLU put forward ... Dr. John Santelli, a pediatrician at the Mailman School of ...
... the super bug hounding them relentlessly. While patients battling ... are quite ‘sick’ with the alien invasion. Of particular ... Clostridium difficile, which networks with gusto among the NHS ... lives annually is also known for its caprice and ...
... a drug that can switch on a gene to burn body ... now pop a pill and burn away all the unwanted fat. ... Biological Studies, California in the US points in that direction. ... even when they did not exercise, and were resistant to weight ...
... patient care. In a recent report the use of RFID (Radio ... who succumb to sudden infant death syndrome each year. ... has come up with a new solution for sudden infant death ... his friends developed a device that can warn a parent when ...
... but also power according to a //recent report. ... retorts, "And you always decide which movie we see." Arguments ... problem only when they are not about specific grievances, but ... Tanja Boeckling, a relationship counselor from Koblenz. Influence must be ...
... Researchers in Melbourne have found a breakthrough method of blood ... measuring the proteins //in blood much before the symptoms arrive. ... Institute, Mental Health Research Institute and Melbourne University specialists. ... which has a broader application as it can screen many ...
Cached Medicine News:Health News:A New Pill to Burn Away Unwanted Fat 2Health News:RFID Use can Avoid Sudden Infant Death Syndrome 2Health News:Relationships are Built on Love and Power 2Health News:New Blood Test to Diagnose Parkinson Disease 2
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
Medicine Products: